Filter by: patients
Home > Community Treatment Reports and Side Effects > Xifaxan Treatment Report
What is Xifaxan?

Xifaxan™ is a brand name for the antibiotic, rifaximin. It is used for the treatment of travelers' diarrhea caused by noninvasive strains of E. coli.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Infection 2 0
Bowel irritability 1 0
Hepatic encephalopathy comatose 1 0
Diarrhea chronic 1 0
Hepatic encephalopathy 1 0
Support immune health 1 0

See all 6 patients currently taking Xifaxan

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  600 mg monthly 200 mg daily 800 mg daily 1,100 mg daily 1,200 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Xifaxan (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 4   Course of treatment ended: 100%

See all 4 patients who’ve stopped taking Xifaxan

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Xifaxan

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Xifaxan

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Xifaxan

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Xifaxan

Very
 0 0%
Somewhat
 1 100%
A little
 0 0%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Xifaxan

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 11, 2012.